Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Whitney P KirschbrownBei WangIhsan NijemAtsushi OhtsuPaulo M HoffManish A ShahLin ShenYoon-Koo KangMaria AlsinaSandhya GirishAmit Garg

Published in: Cancer chemotherapy and pharmacology (2019)

Pertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. The 840 mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears to be an appropriate dose selection.

Keyphrases

epidermal growth factor receptor
end stage renal disease
metastatic breast cancer
chronic kidney disease
ejection fraction
squamous cell carcinoma
small cell lung cancer
papillary thyroid
neoadjuvant chemotherapy
radiation therapy
squamous cell
young adults